Action of chelators in iron-loaded cardiac cells: Accessibility to intracellular labile iron and functional consequences.
about
Drug-induced reactivation of apoptosis abrogates HIV-1 infectionβ-thalassemia intermedia: a clinical perspectiveTransition metals and mitochondrial metabolism in the heartIron chelation and multiple sclerosisIron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseasesIn Vitro Characterization of the Pharmacological Properties of the Anti-Cancer Chelator, Bp4eT, and Its Phase I MetabolitesIron redistribution as a therapeutic strategy for treating diseases of localized iron accumulation.Post-acute pathological changes in the thalamus and internal capsule in aged mice following controlled cortical impact injury: a magnetic resonance imaging, iron histochemical, and glial immunohistochemical study.Combined therapy with idebenone and deferiprone in patients with Friedreich's ataxia.Safety and efficacy of combined chelation therapy with deferasirox and deferoxamine in a gerbil model of iron overload.Antioxidant-mediated effects in a gerbil model of iron overloadThalassaemia is a tropical disease.Cardiac iron across different transfusion-dependent diseases.Design of iron chelators with therapeutic application.Comparison of various iron chelators and prochelators as protective agents against cardiomyocyte oxidative injury.Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cellsFacile transfer of [2Fe-2S] clusters from the diabetes drug target mitoNEET to an apo-acceptor proteinStructure-activity relationships of novel salicylaldehyde isonicotinoyl hydrazone (SIH) analogs: iron chelation, anti-oxidant and cytotoxic properties.Discerning the Chemistry in Individual Organelles with Small-Molecule Fluorescent Probes.The heart in transfusion dependent homozygous thalassaemia today--prediction, prevention and management.Pathophysiology and Clinical Manifestations of the β-Thalassemias.Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection.Novel and potent anti-tumor and anti-metastatic di-2-pyridylketone thiosemicarbazones demonstrate marked differences in pharmacology between the first and second generation lead agents.Combined chelation therapy with deferasirox and deferoxamine in thalassemia.Modern treatment of thalassaemia intermedia.Characterization of cytoprotective and toxic properties of iron chelator SIH, prochelator BSIH and their degradation products.Challenges in the development of magnetic particles for therapeutic applications.Deferasirox: an update.Assessment and treatment of cardiac iron overload in thalassemia.Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments.Cardiac function and iron chelation in thalassemia major and intermedia: a review of the underlying pathophysiology and approach to chelation management.Complications of thalassemia major and their treatment.Deferasirox: pharmacokinetics and clinical experience.Iron toxicity in neurodegeneration.Iron chelation therapy in the management of transfusion-related cardiac iron overload.Visualizing metal ions in cells: an overview of analytical techniques, approaches, and probes.Deferasirox for the treatment of iron overload in non-transfusion-dependent thalassemia.Labile iron in cells and body fluids: physiology, pathology, and pharmacology.Deferasirox: a review of its use for chronic iron overload in patients with non-transfusion-dependent thalassaemia.Iron-sensitive fluorescent probes: monitoring intracellular iron pools.
P2860
Q21090718-821765FB-1AF7-4DFA-93FC-69418B7E93A5Q26828512-4C240AEB-ABF2-464D-99E9-ABA1E88AB570Q26999334-A16D666D-F2A5-49B1-9A54-1E3218238AE1Q27001743-15C776B1-A6EB-4947-B896-680945C169CCQ28388335-09AAC2BA-FA19-4F9A-BF49-41EDE540ED43Q28550205-CB4C197F-0A43-42EF-AE71-1D64A5494347Q33555894-90034AC6-33D1-45DB-AD6C-80EBA8FEE451Q33693872-73A5B9AF-3C0A-41E3-BF7A-1AEA4AA31A1AQ33701891-66BD6914-9CB6-4A05-9333-B28EBC7D4682Q33909024-D45D27C6-8D1F-458E-AE05-77D3B186CAFAQ33944090-66033915-6E22-4AA8-BFF2-477A8C7C18F4Q33950343-496EC82C-6F75-4C32-ABAB-D77DAF47F3DBQ33958560-6C017199-B294-4A20-8ECD-5C45EAFBB938Q34258805-3199F650-2563-4EE7-BF8D-8A550255384FQ34568034-D32F6560-1C9C-4765-814C-D1BF432BE5F5Q35014803-73C4D60B-D7DB-4E1C-999A-F99ADE77E108Q35164588-AA3B8714-0357-43BB-BD68-008E6D5240C7Q35418008-379CD346-6207-4322-A2F9-DB5E8CAAF9A3Q36115905-9BC1A993-C82A-47B1-A884-4E745F21DE8AQ36477489-50B9D983-E81C-44CF-B838-C2B23340B94DQ36526536-F3798BF9-69A8-4772-8C9A-7241C77260DCQ36568908-AB3382F8-292E-492F-91E4-E23FD1195E4FQ36618876-E1F90216-AB44-4ECB-8FA8-7A5906E305DEQ36670257-EBE511CA-4342-40FB-BDF3-E1CCC98CCF29Q36848269-6699FA3B-2E6E-4539-A002-6CEAE8B6276BQ36957543-997F0222-2A18-44D8-A045-E1AC1945B7F5Q37209899-9AA8A70D-0506-4839-B4C5-198C8847B50EQ37650465-4A9E9546-CB1F-475F-B2AA-1676E7B2F35EQ37650479-C51D6100-5C79-4EFC-A817-CE23CB6A2970Q37833060-C60AF2A7-C788-4BBF-AE50-ED9A64439864Q37854465-7A67173E-3FCA-495B-BD92-CF5954C7AF79Q37888721-4B510F16-5A5B-44CB-B170-3908BBA5B838Q37969225-B696CA94-59A9-405A-A910-A8FCD4F4EEB1Q37982648-91550E6D-ADEB-471A-9B3E-443156F6B1DEQ37992181-168063E5-DB3C-4712-8EDE-C7A67FF090BEQ38004261-0B228890-3214-4811-AF66-CE9F1BD3148FQ38148200-F081E691-9A1B-42B1-9D5D-99FD317CA397Q38198634-36F13FEA-11A0-4B31-97E1-728C39DBCF76Q38219588-B5E2F00F-AE8C-4889-B7C0-6B9893D5CF62Q38260227-A14418DC-A6F1-4946-881F-EA76524A2C25
P2860
Action of chelators in iron-loaded cardiac cells: Accessibility to intracellular labile iron and functional consequences.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Action of chelators in iron-lo ...... n and functional consequences.
@ast
Action of chelators in iron-lo ...... n and functional consequences.
@en
type
label
Action of chelators in iron-lo ...... n and functional consequences.
@ast
Action of chelators in iron-lo ...... n and functional consequences.
@en
prefLabel
Action of chelators in iron-lo ...... n and functional consequences.
@ast
Action of chelators in iron-lo ...... n and functional consequences.
@en
P2093
P1433
P1476
Action of chelators in iron-lo ...... n and functional consequences.
@en
P2093
Abraham M Konijn
Chaim Hershko
Hanspeter Nick
Hava Glickstein
Rinat Ben El
William Breuer
Z Ioav Cabantchik
P304
P356
10.1182/BLOOD-2006-05-020867
P407
P577
2006-07-11T00:00:00Z